| Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study N Wanlapakorn, N Suntronwong, H Phowatthanasathian, R Yorsaeng, ... Human vaccines & immunotherapeutics 18 (1), 2029111, 2022 | 71 | 2022 |
| Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine S Kanokudom, S Assawakosri, N Suntronwong, C Auphimai, P Nilyanimit, ... Vaccines 10 (1), 86, 2022 | 69 | 2022 |
| Positive impact of lockdown on COVID-19 outbreak in Thailand S Dechsupa, S Assawakosri, S Phakham, S Honsawek Travel Med Infect Dis 36 (101802), 10.1016, 2020 | 65 | 2020 |
| Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults R Yorsaeng, N Suntronwong, H Phowatthanasathian, S Assawakosri, ... Vaccine 40 (3), 524-530, 2022 | 62 | 2022 |
| Neutralizing activities against the Omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination S Assawakosri, S Kanokudom, N Suntronwong, C Auphimai, P Nilyanimit, ... The Journal of infectious diseases 226 (8), 1372-1381, 2022 | 51 | 2022 |
| COVID-19 breakthrough infection after inactivated vaccine induced robust antibody responses and cross-neutralization of SARS-CoV-2 variants, but less immunity against Omicron N Suntronwong, R Yorsaeng, J Puenpa, C Auphimai, T Thongmee, ... Vaccines 10 (3), 391, 2022 | 24 | 2022 |
| Effects of boosted mRNA and adenoviral‐vectored vaccines on immune responses to omicron BA. 1 and BA. 2 following the heterologous CoronaVac/AZD1222 vaccination N Suntronwong, S Kanokudom, C Auphimai, S Assawakosri, T Thongmee, ... Journal of Medical Virology 94 (12), 5713-5722, 2022 | 23 | 2022 |
| Immunogenicity following two doses of the BBIBP-CorV vaccine and a third booster dose with a viral vector and mRNA COVID-19 vaccines against delta and omicron variants in prime … J Chansaenroj, N Suntronwong, S Kanokudom, S Assawakosri, ... Vaccines 10 (7), 1071, 2022 | 23 | 2022 |
| Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens S Kanokudom, J Chansaenroj, N Suntronwong, S Assawakosri, ... International Journal of Infectious Diseases 126, 64-72, 2023 | 18 | 2023 |
| Strong correlations between the binding antibodies against wild-type and neutralizing antibodies against Omicron BA. 1 and BA. 2 variants of SARS-CoV-2 in individuals following … N Suntronwong, S Assawakosri, S Kanokudom, R Yorsaeng, C Auphimai, ... Diagnostics 12 (8), 1781, 2022 | 16 | 2022 |
| Persistence of immunity against Omicron BA. 1 and BA. 2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 … S Assawakosri, S Kanokudom, J Chansaenroj, N Suntronwong, ... International Journal of Infectious Diseases 122, 793-801, 2022 | 13 | 2022 |
| Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine S Kanokudom, S Assawakosri, N Suntronwong, J Chansaenroj, ... Vaccine 40 (39), 5657-5663, 2022 | 12 | 2022 |
| Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults [Internet]. 2021 sep [citado el 26 de septiembre … R Yorsaeng, N Suntronwong, H Phowatthanasathian, S Assawakosri, ... Preprint, 0 | 7 | |
| SARS-CoV-2 infection-induced seroprevalence among children and associated risk factors during the pre-and omicron-dominant wave, from January 2021 through December 2022 … N Suntronwong, P Vichaiwattana, S Klinfueng, J Puenpa, S Kanokudom, ... Plos one 18 (4), e0279147, 2023 | 6 | 2023 |
| Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand N Wanlapakorn, N Suntronwong, S Kanokudom, S Assawakosri, ... Pathogens and Global Health 116 (7), 395-397, 2022 | 6 | 2022 |
| Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine … S Kanokudom, S Assawakosri, N Suntronwong, C Auphimai, P Nilyanimit, ... DOI: https://doi. org/10.3390/vaccines10010086, 0 | 6 | |
| SARS-CoV-2 antibody dynamics after COVID-19 vaccination and infection: A real-world cross-sectional analysis R Yorsaeng, K Atsawawaranunt, N Suntronwong, S Kanokudom, ... Vaccines 11 (7), 1184, 2023 | 5 | 2023 |
| Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: A cross-sectional survey from October 2022 to January 2023 J Chansaenroj, N Suntronwong, S Kanokudom, S Assawakosri, ... Scientific Reports 13 (1), 15595, 2023 | 4 | 2023 |
| Neutralizing antibodies against Omicron BA. 5 among children with infection alone, vaccination alone, and hybrid immunity N Suntronwong, S Kanokudom, S Assawakosri, P Vichaiwattana, ... International Journal of Infectious Diseases 134, 18-22, 2023 | 4 | 2023 |
| The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA. 4/BA. 5 S Kanokudom, J Chansaenroj, N Suntronwong, S Assawakosri, ... Vaccines 11 (3), 570, 2023 | 4 | 2023 |
Yong PoovorawanProfessor of pediatrics, Chulalongkorn university, Bangkok, ThailandVerified email at chula.ac.th
